All Stories

  1. Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis

    Article • Molecular Pharmacology, April 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mark giembycz

  2. Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the Adverse and Therapeutic Effects of β2-Adrenoceptor Agonists

    Article • Journal of Pharmacology and Experimental Therapeutics, April 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mark giembycz

  3. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells

    Article • Journal of Pharmacology and Experimental Therapeutics, December 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mark giembycz

  4. The long-acting β2-adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent manner

    Article • British Journal of Pharmacology, March 2015, Wiley

    Dr Mark giembycz

  5. An analysis of glucocorticoid receptor-mediated gene expression in BEAS-2B human airway epithelial cells identifies distinct, ligand-directed, transcription profiles with implications for asthma therapeutics

    Article • British Journal of Pharmacology, January 2015, Wiley

    Dr Mark giembycz

  6. Prostanoid receptor antagonists: development strategies and therapeutic applications

    Article • British Journal of Pharmacology, September 2009, Wiley

    Dr Mark giembycz

  7. Alkylxanthines and Phosphodiesterase 4 Inhibitors for Allergic Diseases

    Article • January 2009, Springer Science + Business Media

    Dr Mark giembycz

  8. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

    Article • British Journal of Pharmacology, October 2008, Wiley

    Dr Mark giembycz

  9. Reinventing the Wheel

    Article • December 2006, Taylor & Francis

    Dr Mark giembycz

  10. Phosphodiesterase 7 (PDE7) as a therapeutic target

    Article • Drugs of the Future, January 2006, Prous Science

    Dr Mark giembycz

  11. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors

    Article • Current Opinion in Pharmacology, June 2005, Elsevier

    Dr Mark giembycz

  12. 4D or not 4D – the emetogenic basis of PDE4 inhibitors uncovered?

    Article • Trends in Pharmacological Sciences, December 2002, Elsevier

    Dr Mark giembycz

  13. Choking the breath out of respiratory diseases!

    Article • Trends in Pharmacological Sciences, May 2001, Elsevier

    Dr Mark giembycz

  14. Are eosinophils out of asthma?

    Article • Trends in Pharmacological Sciences, February 2001, Elsevier

    Dr Mark giembycz

  15. Asthma: Epidemiology, Anti-Inflammatory Therapy and Future Trends

    Article • January 2000, Springer Science + Business Media

    Dr Mark giembycz

  16. Phosphodiesterase inhibitors for respiratory diseases

    Article • January 2000, Springer Science + Business Media

    Dr Mark giembycz

  17. Rhinitis: Immunopathology and Pharmacotherapy

    Article • January 1997, Springer Science + Business Media

    Dr Mark giembycz

  18. Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists in asthma

    Article • Trends in Pharmacological Sciences, September 1996, Elsevier

    Dr Mark giembycz

  19. Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists in asthma

    Article • Trends in Pharmacological Sciences, September 1996, Elsevier

    Dr Mark giembycz

  20. Airways Smooth Muscle: Modelling the Asthmatic Response In Vivo

    Article • January 1996, Springer Science + Business Media

    Dr Mark giembycz

  21. Interaction of PDE4 Inhibitors with Enzymes and Cell Functions

    Article • January 1996, Elsevier

    Dr Mark giembycz

  22. Selective Phosphodiesterase Inhibitors in the Therapy of Asthma

    Article • Clinical Immunotherapeutics, June 1995, Springer Science + Business Media

    Dr Mark giembycz

  23. Airways Smooth Muscle: Neurotransmitters, Amines, Lipid Mediators and Signal Transduction

    Article • January 1995, Springer Science + Business Media

    Dr Mark giembycz

  24. Airways Smooth Muscle: Peptide Receptors, Ion Channels and Signal Transduction

    Article • January 1995, Springer Science + Business Media

    Dr Mark giembycz

  25. Antispasmogenic activity of phosphodiesterase inhibitors in guinea-pig trachea

    Article • Pharmacological Research, January 1995, Elsevier

    Dr Mark giembycz

  26. Airways Smooth Muscle

    Article • January 1994, Springer Science + Business Media

    Dr Mark giembycz

  27. Airways Smooth Muscle: Development, and Regulation of Contractility

    Article • January 1994, Springer Science + Business Media

    Dr Mark giembycz

  28. Airways Smooth Muscle: Biochemical Control of Contraction and Relaxation

    Article • January 1994, Springer Science + Business Media

    Dr Mark giembycz

  29. Current concepts on mechanisms of force generation and maintenance in airways smooth muscle

    Article • Pulmonary Pharmacology, December 1992, Elsevier

    Dr Mark giembycz

  30. Forskolin inhibits leukotriene D4-induced thromboxane B2 release from guinea-pig lung parenchyma

    Article • Prostaglandins, November 1984, Elsevier

    Dr Mark giembycz

  31. Theophylline and Isoenzyme-Selective Phosphodiesterase Inhibitors

    Article • Wiley

    Dr Mark giembycz

  32. Mitogen-Activated Protein Kinase Activation in Eosinophils

    Article • Springer Science + Business Media

    Dr Mark giembycz

  33. Human Eosinophil Isolation and the Measurement of Apoptosis

    Article • Springer Science + Business Media

    Dr Mark giembycz